Saturday 17 October 2026
Export NTBLQ’s income statement to Excel — free account
Notable Labs, Ltd.
NTBLQ Healthcare Biotechnology
Revenue growth for three consecutive years.
0.00
0.00
NaN
Follow NTBLQ
Notable Labs, Ltd. (NTBLQ) P/E ratio
Notable Labs, Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.6× (April 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.1× | (83.65%) |
| Mar 2024 | 0.6× | — |
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| 18 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.6×
Ten-year median
0.0×
Current reading's percentile
93
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| NTBLQ Notable Labs, Ltd. | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| EIGRQ Eiger BioPharmaceuticals, Inc. compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)